StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Iovance Biotherapeutics's operating margin for the twelve months ending Jun 30, 2026 was -92.7%. For fiscal 2025 it was -153.1%, against -240.9% the year before.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-153.1%+87.8
FY2024Dec 31, 2024-240.9%+38494.1
FY2023Dec 31, 2023-38735.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-52.3%+137.5
Q1 FY2026Mar 31, 2026-113.5%+132.3
Q4 FY2025Dec 31, 2025-84.7%+32.8
Q3 FY2025Sep 30, 2025-140.7%+11.4
Q2 FY2025Jun 30, 2025-189.8%+137.9
Q1 FY2025Mar 31, 2025-245.8%+16218.9
Q4 FY2024Dec 31, 2024-117.5%+25039.4
Q3 FY2024Sep 30, 2024-152.1%+25084.8
Q2 FY2024Jun 30, 2024-327.6%+45927.0
Q1 FY2024Mar 31, 2024-16464.6%–
Q4 FY2023Dec 31, 2023-25156.8%–
Q3 FY2023Sep 30, 2023-25236.9%–
Q2 FY2023Jun 30, 2023-46254.6%–

More Iovance Biotherapeutics figures

See a number that looks wrong?